Pilot Study of Using Granulocyte Colony Stimulating Factor-Primed Bone Marrow in Histocompatible Sibling Allogeneic Bone Marrow Transplantation for Patients With Hematologic Malignancies and Non-Malignancies
Sponsor study identifier
interventional
10
1 country
1
Study Start
July 2003
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
November 2011
Actual (reported)Study Completion
November 2011
Actual (reported)The major purpose of this study is to evaluate the curative potential of white cell growth hormone (G-CSF)-stimulated bone marrow cells in allogeneic bone marrow transplants. Patients with cancers or blood diseases, who have poor potential for a cure with standard treatment, will be able to participate in the study. Donors will receive the white cell growth hormone (G-CSF) as a shot (injection) in their arm once a day for three days before they donate their bone marrow cells. Total body irradiation and/or chemotherapy will be given first to prepare the patient's body for the infusion of new bone marrow cells from the donor. Two medicines (cyclosporine and methotrexate) will be used to prevent the new bone marrow cells (graft) from attacking the patient's body (host) (graft-versus-host disease; GVHD). Certain safety checkpoints were built into the study if unwanted/unexpected events were to occur. If the outcomes appear better than could be expected, this will provide a bridge to extend this current approach for other innovative therapies.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
November 2011
Actual (reported)Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
July 2003
Date type not reportedThis date has not been verified as actual or estimated.
October 3, 2005
Actual (reported)October 4, 2005
Actual (reported)November 2011
Actual (reported)November 2011
Actual (reported)August 19, 2014
Actual (reported)Numbers of Participants With Disease-free Survival.
Evaluate the numbers of participants with disease-free survival
260 days
Hospital Length of Stay
inpatient hospital stay
Children's Healthcare of Atlanta/Emory University
Atlanta, Georgia, 30322, United States
Our study is also limited by its small patient population and short follow-up time.
Kuang-Yueh Chiang, M.D.
Emory University/CHOA
10 participants (actual enrollment reported by the registry).
First Submitted
October 3, 2005
First Posted
October 4, 2005
Study Start
July 2003
Date type not reportedThis date has not been verified as actual or estimated.
Contact the study team to confirm eligibility.
Primary Completion
November 2011
Actual (reported)Study Completion
November 2011
Actual (reported)Last Updated
August 22, 2014
Results First Posted
August 19, 2014
Record last verified: 2014-08
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: